Tesamorelin — Egrifta & Compounding
Tesamorelin: FDA-approved as Egrifta for HIV-associated lipodystrophy, current compounding availability and off-label considerations.
Evidence-based answer
Tesamorelin: FDA-approved as Egrifta for HIV-associated lipodystrophy, current compounding availability and off-label considerations.
Regulatory status: Tesamorelin is FDA approved as Egrifta SV for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general anti-aging or routine weight-loss drug.
How it works
Tesamorelin is a growth-hormone-releasing factor analog that stimulates pituitary growth hormone and increases IGF-1.
Mechanism is context, not proof. A defensible claim requires human outcome data for the exact molecule, formulation, dose and population. Receptor activity alone cannot establish how much weight a patient will lose, whether an injury will heal or whether a compounded vial has the identity and potency of a trial product.
What the clinical evidence shows
Randomized trials support reduction of visceral adipose tissue in HIV-associated lipodystrophy. That indication cannot be generalized to cosmetic fat loss or bodybuilding.
| Study or evidence level | Population | Intervention | Main result | Interpretation |
|---|---|---|---|---|
| Evidence grade | Varies by molecule | Exact product and route required | See primary sources | Do not extrapolate animal or mechanism data to human outcomes |
Clinical-use framework
Use follows the approved product label and reconstitution instructions; compounded wellness protocols are a different regulatory and evidence category.
A safe plan includes medical history, medication reconciliation, pregnancy screening where relevant, contraindication review, a written titration or administration schedule, missed-dose instructions, side-effect escalation and follow-up. Laboratory testing is individualized; a universal panel is not evidence-based for every patient, but clinicians may order testing based on symptoms, comorbidities and the medicine considered.
How to evaluate an online program
- Identify the legal entities. The marketing company, prescribing practice and dispensing pharmacy may be different organizations.
- Confirm the clinician. Look for a full name, credential, NPI where applicable and authority to practice in the patient’s state.
- Read the prescription label. Verify the exact drug, salt or base, concentration, directions, facility and beyond-use date.
- Normalize cost. Add medication, membership, visits, labs, supplies, shipping and dose surcharges.
- Match the evidence. Ask whether the offered dose and route were studied for the claimed outcome.
- Review continuity. Understand refills, cold-chain handling, replacement, pharmacy changes and cancellation.
Safety
Labeling addresses malignancy, elevated IGF-1, fluid retention, glucose intolerance, hypersensitivity and pregnancy. Monitoring is indication specific.
This page is educational and does not replace diagnosis or individualized prescribing. Severe symptoms, suspected overdose or a serious allergic reaction require urgent in-person evaluation.
Frequently asked questions
Is tesamorelin FDA approved?
Tesamorelin is FDA approved as Egrifta SV for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general anti-aging or routine weight-loss drug.
What is the strongest evidence for tesamorelin?
Randomized trials support reduction of visceral adipose tissue in HIV-associated lipodystrophy. That indication cannot be generalized to cosmetic fat loss or bodybuilding.
Can a compounded or microdose product claim the same trial result?
Not automatically. The trial result applies most directly to the studied product, dose, titration, population and duration. A different formulation, route or lower dose requires its own evidence.
What should be verified before treatment?
Verify the exact product, indication, prescriber, pharmacy, concentration, dose schedule, recurring cost, commitment, follow-up plan and urgent-care instructions.
Primary sources
- Egrifta SV prescribing information Primary clinical or regulatory source
Provider marketing can document what is offered; it is not used as proof of safety or comparative effectiveness. Evidence was reviewed through July 12, 2026.